Vaborbaktaami (Finnish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vaborbaktaami" in Finnish language version.

refsWebsite

Global rank Finnish rank

3,555^th place

4,203^rd place

195^th place

238^th place

1,248^th place

1,162^nd place

447^th place

676^th place

68^th place

51^st place

acs.org

Scott J. Hecker, K. Raja Reddy, Maxim Totrov, Gavin C. Hirst, Olga Lomovskaya, David C. Griffith, Paula King, Ruslan Tsivkovski, Dongxu Sun, Mojgan Sabet, Ziad Tarazi, Matthew C. Clifton, Kateri Atkins, Amy Raymond, Kristy T. Potts, Jan Abendroth, Serge H. Boyer, Jeffrey S. Loutit, Elizabeth E. Morgan, Stephanie Durso & Michael N. Dudley: Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. Journal of Medicinal Chemistry, 2015, 58. vsk, nro 9, s. 3682–3692. Artikkelin verkkoversio. Viitattu 13.11.2019. (englanniksi)

David C. Griffith, Jeffery S. Loutit, Elizabeth E. Morgan, Stephanie Durso & Michael N. Dudley: Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2016, 60. vsk, nro 10, s. 6326–6332. Artikkelin verkkoversio. Viitattu 13.11.2019. (englanniksi)
Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio, Kirk Nelson, Ruslan Tsivkovski, David C. Griffith & Michael N. Dudley: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2017, 61. vsk, nro 11, s. e01443-17. Artikkelin verkkoversio. Viitattu 13.11.2019. (englanniksi)

Vabomere (meropeneemi/vaborbaktaami) 2018. Euroopan lääkevirasto. Viitattu 13.11.2019.

FDA approves new antibacterial drug 29.8.2017. FDA. Viitattu 13.11.2019. (englanniksi)

WHO Model List of Essential Medicines 2019. WHO. Viitattu 11.11.2019. (englanniksi)